Signaling, Delivery and Age as Emerging Issues in the Benefit/Risk Ratio Outcome of tPA For Treatment of CNS Ischemic Disorders

Stroke is a leading cause of morbidity and mortality. While tissue-type plasminogen activator (tPA) remains the only FDA approved treatment for ischemic stroke, clinical use of tPA has been constrained to roughly 3% of eligible patients because of the danger of intracranial hemorrhage and a narrow 3...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Armstead, William M, Ganguly, Kumkum, Kiessling, JW, Riley, John, Chen, Xiao-Han, Smith, Douglas H, Stein, Sherman C., Higazi, Abd AR, Cines, Douglas B, Bdeir, Khalil, Zaitsev, Sergei, Muzykantov, Vladimir R.
Format: Artigo
Jezik:Inglês
Izdano: 2010
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3467975/
https://ncbi.nlm.nih.gov/pubmed/20405577
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki